MA27715A1 - Nouveaux composes d'arylpiperazinyle - Google Patents
Nouveaux composes d'arylpiperazinyleInfo
- Publication number
- MA27715A1 MA27715A1 MA28470A MA28470A MA27715A1 MA 27715 A1 MA27715 A1 MA 27715A1 MA 28470 A MA28470 A MA 28470A MA 28470 A MA28470 A MA 28470A MA 27715 A1 MA27715 A1 MA 27715A1
- Authority
- MA
- Morocco
- Prior art keywords
- novel
- relates
- arylpiperazinyl
- compounds
- disorders
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 abstract 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 abstract 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 abstract 1
- 102000014630 G protein-coupled serotonin receptor activity proteins Human genes 0.000 abstract 1
- 208000011688 Generalised anxiety disease Diseases 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000029364 generalized anxiety disease Diseases 0.000 abstract 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000001537 neural effect Effects 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229940124530 sulfonamide Drugs 0.000 abstract 1
- -1 sulfonamide compounds Chemical class 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/96—Sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Gynecology & Obstetrics (AREA)
- Rheumatology (AREA)
- Psychology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
L'invention concerne des agonistes ou des antagonistes du récepteur 5-HT. L'invention concerne également de nouveaux composés de sulfonamide d'arylpipérazinyle représentés par la formule (I), leur synthèse et leur utilisation pour traiter des maladies induites directement ou indirectement par les récepteurs 5-HT. Ces états pathologiques comprennent les troubles du système nerveux central tels les troubles d'anxiété généralisée, ADD/ADHD, les blessures neurales, les accidents cérébro-vasculaires et les migraines. L'invention concerne enfin des procédés de préparation, de nouveaux intermédiaires et des sels pharmaceutiques de ceux-ci.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US44398803P | 2003-01-31 | 2003-01-31 | |
US45829703P | 2003-03-28 | 2003-03-28 | |
US50352003P | 2003-09-16 | 2003-09-16 | |
US10/768,579 US7153858B2 (en) | 2003-01-31 | 2004-01-30 | Arylpiperazinyl compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
MA27715A1 true MA27715A1 (fr) | 2006-01-02 |
Family
ID=32854494
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA28470A MA27715A1 (fr) | 2003-01-31 | 2005-08-29 | Nouveaux composes d'arylpiperazinyle |
Country Status (11)
Country | Link |
---|---|
US (3) | US7153858B2 (fr) |
EP (1) | EP1592425A4 (fr) |
JP (2) | JP4787148B2 (fr) |
KR (1) | KR20060010717A (fr) |
AU (1) | AU2004209020B2 (fr) |
BR (1) | BRPI0407175A (fr) |
CA (1) | CA2513915C (fr) |
MA (1) | MA27715A1 (fr) |
MX (1) | MXPA05008212A (fr) |
NO (1) | NO20054005L (fr) |
WO (1) | WO2004069794A2 (fr) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7153858B2 (en) * | 2003-01-31 | 2006-12-26 | Epix Delaware, Inc. | Arylpiperazinyl compounds |
US20050222175A1 (en) * | 2004-03-31 | 2005-10-06 | Dhanoa Dale S | New piperidinylamino-thieno[2,3-D] pyrimidine compounds |
US7612078B2 (en) * | 2003-03-31 | 2009-11-03 | Epix Delaware, Inc. | Piperidinylamino-thieno[2,3-D] pyrimidine compounds |
AR047759A1 (es) * | 2003-09-26 | 2006-02-22 | Vertex Pharma | Derivados de fenil - piperazina como moduladores de receptores muscarnicos |
US7488736B2 (en) * | 2004-05-17 | 2009-02-10 | Epix Delaware, Inc. | Thienopyridinone compounds and methods of treatment |
US7598265B2 (en) * | 2004-09-30 | 2009-10-06 | Epix Delaware, Inc. | Compositions and methods for treating CNS disorders |
US7576211B2 (en) * | 2004-09-30 | 2009-08-18 | Epix Delaware, Inc. | Synthesis of thienopyridinone compounds and related intermediates |
US7407966B2 (en) * | 2004-10-07 | 2008-08-05 | Epix Delaware, Inc. | Thienopyridinone compounds and methods of treatment |
CA2595607C (fr) | 2005-01-25 | 2014-07-15 | Epix Delaware, Inc. | Composes d'arylamine substitues et leur utilisation comme modulateurs de 5-ht6 |
MX2007012242A (es) * | 2005-03-29 | 2008-03-18 | Johnson & Johnson | Ciclohexan-1,4-diaminas sustituidas con piperacinilo. |
CA2694621C (fr) | 2007-08-07 | 2015-01-06 | Prosarix Limited | Nouveaux modulateurs serotonergiques |
TW200914020A (en) * | 2007-08-28 | 2009-04-01 | Lilly Co Eli | Substituted piperazinyl pyrazines and pyridines as 5-HT7 receptor antagonists |
US20090281112A1 (en) * | 2008-05-08 | 2009-11-12 | Fabre-Kramer Pharmaceuticals, Inc. | Adatanserin and metabolites thereof for treatment of attention deficit disorder, anxiety, depression, sexual dysfunction, and other disorders |
BRPI0912516A2 (pt) * | 2008-05-08 | 2015-10-13 | Fabre Kramer Pharmaceuticals Inc | 3-hidróxi gepirona para o tratamento de distúrbio de défict de atenção e disfunção sexual |
WO2010065743A2 (fr) * | 2008-12-03 | 2010-06-10 | Nanotherapeutics, Inc. | Composés bicycliques et leurs procédés de fabrication et d'utilisation |
US8927553B2 (en) * | 2009-08-10 | 2015-01-06 | Daljit Singh Dhanoa | Deuterium-enriched alkyl sulfonamides and uses thereof |
US8530479B2 (en) * | 2009-08-10 | 2013-09-10 | Daljit Singh Dhanoa | Deuterium-enriched alkyl sulfonamides |
PL392436A1 (pl) | 2010-09-17 | 2012-03-26 | Adamed Spółka Z Ograniczoną Odpowiedzialnością | Pochodne arylosulfonamidów do leczenia chorób odśrodkowego układu nerwowego |
US9901827B2 (en) * | 2015-01-06 | 2018-02-27 | Spin Master Ltd. | Methods and system relating to physical constructions and virtual representations |
KR102571028B1 (ko) | 2016-12-20 | 2023-08-28 | 래쉬파이 인코포레이티드 | 인공 속눈썹 연장부에 사용하는 어플리케이터 및 케이스 |
KR20210110177A (ko) | 2019-01-14 | 2021-09-07 | 래쉬파이 인코포레이티드 | 속눈썹 연장물 및 그의 제조 및 사용 방법 |
CN211747241U (zh) | 2019-10-03 | 2020-10-27 | 莱施菲公司 | 人造睫毛装置及睫毛延长装置 |
KR102447231B1 (ko) * | 2020-05-29 | 2022-09-27 | 재단법인 대구경북첨단의료산업진흥재단 | 설폰아미드 유도체 및 이를 유효성분으로 함유하는 정신질환의 예방 또는 치료용 약학적 조성물 |
JP2023528545A (ja) * | 2020-05-29 | 2023-07-04 | テグ-キョンプク メディカル イノベーション ファウンデーション | スルホンアミド誘導体およびそれを有効成分とする精神病の予防または治療に使用するための医薬組成物 |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2722529A (en) * | 1955-11-01 | Amides of certain l-amevoalkyl-x-phenyl | ||
DK101683A (da) * | 1982-03-12 | 1983-09-13 | Duphar Int Res | Phenylpiperazinderivater og fremgangsmaade til fremstilling heraf |
JPS5929665A (ja) * | 1982-08-11 | 1984-02-16 | Sumitomo Chem Co Ltd | ピペラジン誘導体及びその酸付加塩 |
JP2556722B2 (ja) * | 1988-02-18 | 1996-11-20 | 興和株式会社 | 新規なスルホンアミド化合物 |
DE3901814A1 (de) | 1988-07-28 | 1990-02-01 | Bayer Ag | Substituierte aminomethylzetraline sowie ihre heterocyclischen analoga |
US5300523A (en) | 1988-07-28 | 1994-04-05 | Bayer Aktiengesellschaft | Substituted aminomethyltetralins and their heterocyclic analogues |
FR2655988B1 (fr) * | 1989-12-20 | 1994-05-20 | Adir Cie | Nouveaux derives de la napht-1-yl piperazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
ZA929008B (en) | 1991-12-13 | 1993-05-21 | Bristol Myers Squibb Co | Piperazinyl- and piperidinyl-cyclohexanols. |
IT1266582B1 (it) * | 1993-07-30 | 1997-01-09 | Recordati Chem Pharm | Derivati (di)azacicloesanici e diazacicloeptanici |
JP3836892B2 (ja) * | 1993-12-27 | 2006-10-25 | トーアエイヨー株式会社 | 置換環状アミン化合物、その製造法及びそれを含有する循環器官用剤 |
EP0661266A1 (fr) * | 1993-12-27 | 1995-07-05 | Toa Eiyo Ltd. | Composés cycliques aminés substitués comme 5HT2 antagonistes |
FR2722788B1 (fr) | 1994-07-20 | 1996-10-04 | Pf Medicament | Nouvelles piperazides derivees d'aryl piperazine, leurs procedes de preparation, leur utilisation a titre de medicament et les compositions pharmaceutiques les comprenant |
US5602124A (en) | 1994-12-12 | 1997-02-11 | Allelix Biopharmaceuticals, Inc. | 5-HT2 receptor ligands |
JPH09202764A (ja) | 1996-01-24 | 1997-08-05 | Chugai Pharmaceut Co Ltd | ニトロ化合物 |
DZ2376A1 (fr) | 1996-12-19 | 2002-12-28 | Smithkline Beecham Plc | Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant. |
ID27976A (id) | 1998-06-19 | 2001-05-03 | Lundbeck & Co As H | 4,5,6 dan 7-indol dan turunan-turunan indolin, pembuatan dan penggunaannya |
AR022303A1 (es) | 1999-01-22 | 2002-09-04 | Lundbeck & Co As H | Derivados de piperidina, tetrahidropiridina y piperazina, su preparacion y utilizacion |
GB9906624D0 (en) | 1999-03-23 | 1999-05-19 | Smithkline Beecham Plc | Novel compounds |
US6465467B1 (en) | 1999-05-21 | 2002-10-15 | Biovitrum Ab | Certain aryl-aliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases |
US7361666B2 (en) | 1999-05-25 | 2008-04-22 | Sepracor, Inc. | Heterocyclic analgesic compounds and methods of use thereof |
US6635661B2 (en) | 2000-05-25 | 2003-10-21 | Sepracor Inc. | Heterocyclic analgesic compounds and methods of use thereof |
WO2001068604A2 (fr) | 2000-03-14 | 2001-09-20 | Sepracor, Inc. | Piperidines 3-substituees comprenant un groupement uree et procedes d'utilisation de ces dernieres |
WO2001092226A1 (fr) | 2000-05-25 | 2001-12-06 | Sepracor, Inc. | Composes analgesiques heterocycliques et technique d'utilisation de ceux-ci |
AU9087301A (en) | 2000-09-11 | 2002-03-26 | Sepracor Inc | Ligands for monoamine receptors and transporters, and methods of use thereof |
WO2002022579A2 (fr) | 2000-09-11 | 2002-03-21 | Sepracor, Inc. | Heterocycles sulfonamides antipsychotiques et leurs methodes d'utilisation |
AU2002237704A1 (en) | 2000-12-04 | 2002-06-18 | Sepracor, Inc. | Methods for the stereoselective synthesis of substituted piperidines |
WO2002069973A1 (fr) | 2001-03-02 | 2002-09-12 | Sepracor, Inc. | Ligand piperidine-piperazine pour recepteurs neurotransmetteurs |
US7115607B2 (en) | 2001-07-25 | 2006-10-03 | Amgen Inc. | Substituted piperazinyl amides and methods of use |
US20030073681A1 (en) | 2001-08-21 | 2003-04-17 | Hauske James R. | 2-substituted piperidines that are ligands for monoamine receptors and transporters |
ATE396971T1 (de) * | 2002-03-13 | 2008-06-15 | Janssen Pharmaceutica Nv | Sulfonylaminoderivate als neue inhibitoren von histondeacetylase |
US7153858B2 (en) * | 2003-01-31 | 2006-12-26 | Epix Delaware, Inc. | Arylpiperazinyl compounds |
CA2595607C (fr) | 2005-01-25 | 2014-07-15 | Epix Delaware, Inc. | Composes d'arylamine substitues et leur utilisation comme modulateurs de 5-ht6 |
-
2004
- 2004-01-30 US US10/768,579 patent/US7153858B2/en not_active Expired - Fee Related
- 2004-02-02 CA CA2513915A patent/CA2513915C/fr not_active Expired - Fee Related
- 2004-02-02 AU AU2004209020A patent/AU2004209020B2/en not_active Expired - Fee Related
- 2004-02-02 EP EP04707409A patent/EP1592425A4/fr not_active Withdrawn
- 2004-02-02 KR KR1020057014179A patent/KR20060010717A/ko not_active Application Discontinuation
- 2004-02-02 BR BR0407175-1A patent/BRPI0407175A/pt not_active IP Right Cessation
- 2004-02-02 MX MXPA05008212A patent/MXPA05008212A/es active IP Right Grant
- 2004-02-02 WO PCT/US2004/002858 patent/WO2004069794A2/fr active Application Filing
- 2004-02-02 JP JP2006503235A patent/JP4787148B2/ja not_active Expired - Fee Related
-
2005
- 2005-08-29 NO NO20054005A patent/NO20054005L/no not_active Application Discontinuation
- 2005-08-29 MA MA28470A patent/MA27715A1/fr unknown
-
2006
- 2006-09-05 US US11/516,345 patent/US7491727B2/en not_active Expired - Fee Related
-
2007
- 2007-07-24 US US11/782,415 patent/US7488731B2/en not_active Expired - Fee Related
-
2011
- 2011-06-06 JP JP2011126287A patent/JP2011207904A/ja not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
AU2004209020A1 (en) | 2004-08-19 |
NO20054005D0 (no) | 2005-08-29 |
KR20060010717A (ko) | 2006-02-02 |
WO2004069794A3 (fr) | 2004-11-04 |
NO20054005L (no) | 2005-10-27 |
US20070004742A1 (en) | 2007-01-04 |
US20080027066A1 (en) | 2008-01-31 |
US7491727B2 (en) | 2009-02-17 |
WO2004069794A2 (fr) | 2004-08-19 |
EP1592425A4 (fr) | 2007-01-24 |
WO2004069794B1 (fr) | 2005-01-27 |
BRPI0407175A (pt) | 2006-02-07 |
CA2513915A1 (fr) | 2004-08-19 |
JP2006516640A (ja) | 2006-07-06 |
JP2011207904A (ja) | 2011-10-20 |
JP4787148B2 (ja) | 2011-10-05 |
WO2004069794A9 (fr) | 2004-12-09 |
CA2513915C (fr) | 2013-04-09 |
AU2004209020B2 (en) | 2009-05-28 |
MXPA05008212A (es) | 2006-01-17 |
AU2004209020A2 (en) | 2004-08-19 |
US20040220192A1 (en) | 2004-11-04 |
EP1592425A2 (fr) | 2005-11-09 |
US7153858B2 (en) | 2006-12-26 |
US7488731B2 (en) | 2009-02-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA27715A1 (fr) | Nouveaux composes d'arylpiperazinyle | |
BRPI0408988A (pt) | composto de piperidinilamino-tieno[2,3-d]pirimidina | |
KR100299624B1 (ko) | 축합벤조화합물 | |
EA199700156A1 (ru) | Производные индола как антагонисты рецептора 5-нт | |
US20030008874A1 (en) | 1,3 disubstituted pyrrolidines as alpha -2- adrenoceptor antagonists | |
MA29211B1 (fr) | Composes de thienopyridinone et methodes therapeutiques | |
DE60231202D1 (de) | Kondensierte heterozyklische verbindungen | |
JP2008536941A (ja) | オキシインドール化合物および治療剤としてのその使用 | |
MA30696B1 (fr) | Derives de l'acide (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetique | |
NO20065814L (no) | Thiendopyridinon forbindelser og fremgangsmater for behandling | |
JP2006522041A (ja) | インドロンアセトアミド誘導体、その調製方法及びその使用 | |
RU2060254C1 (ru) | Замещенные 3-(пиридиниламино)-индолы или -бензо(в)тиофены и способ их получения | |
DE60111464D1 (de) | Azabicycloalkan-Derivate zur Verwendung als Inhibitoren der Serotonin-Wiederaufnahme und als 5HT2a Antagonisten | |
EP0605697A1 (fr) | Derives d'indole utilises dans le traitement de la migraine | |
DE3851907T2 (de) | Aliphatische Carboxamide. | |
Berg et al. | (R)-(+)-2-[[[3-(Morpholinomethyl)-2 H-chromen-8-yl] oxy] methyl] morpholine Methanesulfonate: A New Selective Rat 5-Hydroxytryptamine1B Receptor Antagonist | |
MA26541A1 (fr) | Nouvelles imidazolines, procede pour les preparer, compositions pharmaceutiques les contenant et leur utilisation dans le traitement de maladies soulagees par un traitement avec un antagoniste des recepteurs des prostaglandines | |
TNSN99056A1 (fr) | Composes azabicycliques substitues nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant | |
CA2430707C (fr) | Methanesulfonate de 8'4-'3-(5-fluoro-1h-indol-3-yl)propyl!-1-piperazinyl!-2-methyl-2h-1, 4-benzoxazin -3(4h)-one a haute affinite pour le recepteur d2 de la dopamine et le site dereabsorption de la serotonine | |
JPH05125024A (ja) | 新規なアリールオキシアルキルアミン誘導体又はその塩 | |
TW546299B (en) | 3,4-dihydro-2H-benzo[1,4]oxazinyl-methyl-[3-(1H-indol-3-yl)-alkyl]-amines | |
BR0112998A (pt) | Derivados de indol úteis para o tratamento de distúrbios do sistema nervoso central (snc); composto; sua utilização; composição farmacêutica e método de tratamento | |
WO2004080407A3 (fr) | Nouveaux composes a modulation de serotinine et utilisations associees | |
ATE386519T1 (de) | Benzimidazole derivate und ihre anwendung als gaba a rezeptor komplex modulatoren | |
EA200701052A1 (ru) | Новые производные замещённого арилпиперазина |